Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The drug and vaccine landscape for neglected diseases (2000-11): A systematic assessment
The Lancet Global Health, Volume 1, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
Background: In 1975-99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011. Methods: We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made between Jan 1, 2000, and Dec 31, 2011. We defined neglected diseases as malaria, tuberculosis, diarrhoeal diseases, neglected tropical diseases (NTDs; WHO definition), and other diseases of poverty according to common definitions. Findings: Of the 850 new therapeutic products registered in 2000-11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in Dec 31, 2011, only 2016 (1%) were for neglected diseases. Interpretation: Our findings show a persistent insufficiency in drug and vaccine development for neglected diseases. Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and delivered to improve control and potentially achieve elimination. © 2013 Pedrique et al. Open Access article distributed under the terms of CC BY-NC-SA.
Authors & Co-Authors
Pedrique, Belén
Switzerland, Geneve
Drugs for Neglected Diseases Initiative Dndi
Strub-Wourgaft, Nathalie
Switzerland, Geneve
Drugs for Neglected Diseases Initiative Dndi
Olliaro, Piero L.
Switzerland, Geneva
Organisation Mondiale de la Santé
United Kingdom, Oxford
University of Oxford
Trouiller, Patrice
France, Saint Martin D'heres
Université Grenoble Alpes
Ford, Nathan P.
Switzerland, Geneva
Medecins Sans Frontieres
Pécoul, Bernard
Switzerland, Geneve
Drugs for Neglected Diseases Initiative Dndi
Statistics
Citations: 224
Authors: 6
Affiliations: 6
Identifiers
Doi:
10.1016/S2214-109X(13)70078-0
ISSN:
2214109X
Research Areas
Health System And Policy
Infectious Diseases